430 related articles for article (PubMed ID: 26872889)
1. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
Toyoda H; Kumada T; Tada T; Takaguchi K; Ishikawa T; Tsuji K; Zeniya M; Iio E; Tanaka Y
J Gastroenterol; 2016 Jul; 51(7):741-7. PubMed ID: 26872889
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
3. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
Miyazaki R; Miyagi K
Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
Nam HC; Lee HL; Yang H; Song MJ
Clin Mol Hepatol; 2016 Jun; 22(2):259-66. PubMed ID: 27377910
[TBL] [Abstract][Full Text] [Related]
5. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
6. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.
Wei L; Wang FS; Zhang MX; Jia JD; Yakovlev AA; Xie W; Burnevich E; Niu JQ; Jung YJ; Jiang XJ; Xu M; Chen XY; Xie Q; Li J; Hou JL; Tang H; Dou XG; Gandhi Y; Hu WH; McPhee F; Noviello S; Treitel M; Mo L; Deng J
World J Gastroenterol; 2018 Mar; 24(12):1361-1372. PubMed ID: 29599611
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
Suda G; Kudo M; Nagasaka A; Furuya K; Yamamoto Y; Kobayashi T; Shinada K; Tateyama M; Konno J; Tsukuda Y; Yamasaki K; Kimura M; Umemura M; Izumi T; Tsunematsu S; Sato F; Terashita K; Nakai M; Horimoto H; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
J Gastroenterol; 2016 Jul; 51(7):733-40. PubMed ID: 26768604
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
Morisawa N; Koshima Y; Satoh JI; Maruyama Y; Kuriyama S; Yokoo T; Amemiya M
Clin Exp Nephrol; 2017 Oct; 21(5):818-824. PubMed ID: 27771774
[TBL] [Abstract][Full Text] [Related]
10. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Toyota J; Karino Y; Suzuki F; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; Hu W; McPhee F; Linaberry M; Yin PD; Swenson ES; Kumada H
J Gastroenterol; 2017 Mar; 52(3):385-395. PubMed ID: 27502287
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.
Lee BS; Song MJ; Kwon JH; Lee TH; Jang JW; Kim SH; Lee SH; Kim HS; Kim JH; Kim SB; Ko SY; Song DS
Gut Liver; 2019 Mar; 13(2):191-196. PubMed ID: 30400729
[TBL] [Abstract][Full Text] [Related]
12. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Wei L; Zhang M; Xu M; Chuang WL; Lu W; Xie W; Jia Z; Gong G; Li Y; Bae SH; Yang YF; Xie Q; Lin S; Chen X; Niu J; Jia J; Garimella T; Torbeyns A; McPhee F; Treitel M; Yin PD; Mo L
J Gastroenterol Hepatol; 2016 Nov; 31(11):1860-1867. PubMed ID: 27003037
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
Nakamura Y; Imamura M; Kawakami Y; Teraoka Y; Daijo K; Honda F; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Chayama K
J Med Virol; 2017 Apr; 89(4):665-671. PubMed ID: 27602542
[TBL] [Abstract][Full Text] [Related]
14. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
Poordad F; Sievert W; Mollison L; Bennett M; Tse E; Bräu N; Levin J; Sepe T; Lee SS; Angus P; Conway B; Pol S; Boyer N; Bronowicki JP; Jacobson I; Muir AJ; Reddy KR; Tam E; Ortiz-Lasanta G; de Lédinghen V; Sulkowski M; Boparai N; McPhee F; Hughes E; Swenson ES; Yin PD;
JAMA; 2015 May; 313(17):1728-35. PubMed ID: 25942723
[TBL] [Abstract][Full Text] [Related]
15. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.
Oh JY; Kim BS; Lee CH; Song JE; Lee HJ; Park JG; Hwang JS; Chung WJ; Jang BK; Kweon YO; Tak WY; Park SY; Jang SY; Suh JI; Kwak SG
Korean J Intern Med; 2019 Jul; 34(4):794-801. PubMed ID: 29792020
[TBL] [Abstract][Full Text] [Related]
16. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
Morio K; Imamura M; Kawakami Y; Morio R; Kobayashi T; Yokoyama S; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Makokha GN; Hayes CN; Aikata H; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Gastroenterol Hepatol; 2017 Mar; 32(3):645-650. PubMed ID: 27513614
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.
Toyoda H; Kumada T; Tada T; Shimada N; Takaguchi K; Senoh T; Tsuji K; Tachi Y; Hiraoka A; Ishikawa T; Shima T; Okanoue T
J Hepatol; 2017 Mar; 66(3):521-527. PubMed ID: 27890790
[TBL] [Abstract][Full Text] [Related]
18. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
Suda G; Furusyo N; Toyoda H; Kawakami Y; Ikeda H; Suzuki M; Arataki K; Mori N; Tsuji K; Katamura Y; Takaguchi K; Ishikawa T; Tsuji K; Shimada N; Hiraoka A; Yamsaki S; Nakai M; Sho T; Morikawa K; Ogawa K; Kudo M; Nagasaka A; Furuya K; Yamamoto Y; Kato K; Ueno Y; Iio E; Tanaka Y; Kurosaki M; Kumada T; Chayama K; Sakamoto N
J Gastroenterol; 2018 Jan; 53(1):119-128. PubMed ID: 28560477
[TBL] [Abstract][Full Text] [Related]
19. Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
Koshino K; Ushigome H; Masuda K; Matsuyama T; Harada S; Nakamura T; Nobori S; Iida T; Yoshimura N
Transplant Proc; 2017 Jun; 49(5):1053-1055. PubMed ID: 28583525
[TBL] [Abstract][Full Text] [Related]
20. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
Akuta N; Toyota J; Karino Y; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; McPhee F; Noviello S; Kumada H
J Gastroenterol; 2018 Sep; 53(9):1089-1097. PubMed ID: 29500489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
